Exact Sciences Corporation
EXAS
株式のランク
#1156
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
株価
$104.91
最終同期: 2026-03-23
時価総額
$20.03B
変化（1日）
0.00%
変化（1年）
67.24%
国
US
取引 Exact Sciences Corporation (EXAS)
カテゴリー
Healthcare
Exact Sciences Corporation（EXAS）のP/E比率
October 2026 時点のP/E比率 TTM -188.59
Exact Sciences Corporation の最新の財務報告および株価によると、現在の P/E (TTM) は -188.59 です。2023 年末時点での P/E は -65.28 でした。
Exact Sciences Corporation の P/E 比率の履歴（2000 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -188.59 | 1,774.61% |
| 2024 | -10.06 | -84.59% |
| 2023 | -65.28 | 366.18% |
| 2022 | -14.00 | -37.46% |
| 2021 | -22.39 | -5.12% |
| 2020 | -23.60 | -83.67% |
| 2019 | -144.52 | 228.25% |
| 2018 | -44.03 | -17.14% |
| 2017 | -53.13 | 549.80% |
| 2016 | -8.18 | 51.73% |
| 2015 | -5.39 | -75.51% |
| 2014 | -22.01 | 29.07% |
| 2013 | -17.05 | 41.89% |
| 2012 | -12.02 | -19.19% |
| 2011 | -14.87 | -28.97% |
| 2010 | -20.93 | 71.17% |
| 2009 | -12.23 | 668.09% |
| 2008 | -1.59 | -78.05% |
| 2007 | -7.26 | 24.90% |
| 2006 | -5.81 | 45.28% |
| 2005 | -4.00 | -23.67% |
| 2004 | -5.24 | -22.43% |
| 2003 | -6.75 | 1.09% |
| 2002 | -6.68 | -7.25% |
| 2001 | -7.20 | 290.36% |
| 2000 | -1.85 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 36.15 | -119.17% |
US
|
|
| 39.77 | -121.09% |
US
|
|
| -290.26 | 53.91% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -118.13% |
US
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。